Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART.
Method
Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects.
Results
Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP®]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load.
Conclusions
The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.
EggerM., HirschelB., FrancioliP., SudreP., WirzM., FleppM., RickenbachM., MalinverniR., VernazzaP., & BattegayM.Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multi-centre study. Swiss HIV cohort study. British Medical Journal1997; 315: 1194–1199.
3.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. New England Journal of Medicine1998; 338(13): 853–860.
4.
McArthurJ.C., McClernonD.R., CroninM.F., Nance-SprosonT.E., SaahA.J., St ClairM., & LanierE.R.Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology1997; 42(5): 689–698.
5.
StingeleK., HaasJ., ZimmermannT., StingeleR., Hubsch-MullerC., FreitagM., Storch-HagenlocherB., HartmannM., & WildemannB.Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology2001; 56(3): 355–361.
6.
CinqueP., PresiS., BestettiA., PierottiC., RaccaS., BoeriE., MorelliP., CarreraP., FerrariM., & LazzarinA.Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Research in Human Retroviruses2001; 17(5): 377–383.
7.
EllisR.J., HsiaK., SpectorS.A., NelsonJ.A., HeatonR.K., WallaceM.R., AbramsonI., AtkinsonJ.H., GrantI., McCutchanJ.A., & Group, HNRC. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Annals of Neurology1997; 42(5): 679–688.
8.
TraceyI., CarrC.A., GuimaraesA.R., WorthJ.L., NaviaB.A., & GonzalezR.G.Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology1996; 46: 783–788.
9.
ChangL., ErnstT., Leonido-YeeM., WalotI., & SingerE.Cerebral metabolite abnormalities correlate with clinical severity of HIV-cognitive motor complex. Neurology1999; 52(1): 100–108.
10.
SacktorN., LylesR., SkolaskyR., AndersonD., McArthurJ., McFarlaneG., SelnesO., BeckerJ., CohenB., WeschJ., & MillerE.Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology1999; 52(8): 1640–1647.
11.
ChangL., ErnstT., Leonido-YeeM., WittM., SpeckO., WalotI., & MillerE.N.Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology1999; 53: 782–789.
JanssenR.S., CornblathD.R., EpsteinL.G., FoaR.P., McArthurJ.C., & PriceR.W.Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology1991; 41: 778–785.
14.
KarnofskyD.A., & BurchenalJ.H.The clinical evaluation of chemotherapeutic agents in cancer.1949; pp. 199–205. Edited by MacLeodC.New York: Columbia University Press.
15.
PowerC., & JohnsonR.T.HIV-1 Associated Dementia: Clinical Features and Pathogenesis. Canadian Journal of Neurological Sciences1995; 22: 92–100.
16.
PriceR., & BrewB.The AIDS Dementia complex. The Journal of Infectious Diseases1988; 158: 1079–1083.
17.
KløveH.Clinical neuropsychology. In The Medical Clinics of North America.1964; pp. 110–125. Edited by ForsterF.New York: WB Saunders.
18.
Anonymous.Army Individual Test Battery: manual of directions and scoring.Washington, DC: War Department, Adjutant General's Office; 1944.
19.
SmithA.Symbol Digit Modalities Test: Western Psychological Services.1982.
20.
ReyA.L'examen psycholoqiue dans les cas d'encephalopathie traumatique. Archives of Psychology1941; 28: 286–340.
21.
StroopJ.Studies of interference in serial verbal reaction. Journal of Experimental Psychology1935; 18: 643–662.
22.
RadloffL.L.The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measures1977; 1: 385–401.
23.
BlairJ., & SpreenO.The New Adult Reading Test – Revised Manual.1989. Victoria, Canada: University of Victoria.
24.
MillerE.N.California Computerized Assessment Package.1990. Edited by Custom. Los Angeles: Norland Software.
25.
UchiyamaC., D'EliaL., DellingerA., SelnesO., BeckerJ., WeschJ., ChenB., SatzP., Van GorpW., MillerE., & the Multicenter, AIDS Cohort Study. Longitudinal comparison of alternate versions of the symbol digit modalities test: issues of form comparability and moderating demographic variables. The Clinical Neuropsychologist1994; 8: 209–218.
26.
UchiyamaC., D'EliaL., DellingerA., BeckerJ., SelnesO., WeschJ., ChenB., SatzP., Van GorpW., MillerE., & the Multicenter, AIDS Cohort Study. Alternative forms of the auditory-verbal learning test: issues of test comparability, longitudinal reliability, and moderating demographic variables. Archives of Clinical Neuropsychology1995; 10: 133–145.
27.
BottomleyP.A.Spatial localization in NMR spectroscopy in vivo. Annals of the New York Academy of Sciences1987; 508: 333–348.
28.
ErnstT., & ChangL.Elimination of artifacts in short echo time 1H MR spectroscopy of the frontal lobe. Magnetic Resonance in Medicine1996; 36: 462–468.
29.
KreisR., ErnstT., & RossB.D.Absolute quantitation of water and metabolites in the human brain. II: metabolite concentrations. Journal of Magnetic Resonance1993; B102: 9–19.
30.
ErnstT., KreisR., & RossB.D.Absolute quantitation of water and metabolites in the human brain. I: compartments and water. Journal of Magnetic Resonance1993; B102: 1–8.
31.
SimesR.J.An improved Bonferroni procedure for multiple tests of significance. Biometrika1986; 73(3): 751–754.
32.
GisslenM., SvennerholmB., NorkransG., FranzenC., SallC., SvenssonR., ObergS., & HagbergL.Cerebrospinal fluid and plasma viral load in HIV-1 infected patients with various anti-retroviral treatment regimens. Scandinavian Journal of Infectious Diseases2000; 32(4): 365–369.
33.
LaubenbergerJ., HaussingerD., BayerS., ThielemannS., SchneiderB., MundingerA., HennigJ., & LangerM.HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology1996; 199: 805–810.
34.
Lopez-VillegasD., LenkinskiR.E., & FrankI.Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proceedings of the National Academy of Sciences, USA1997; 94(18): 9854–9859.
35.
von GiesenH., WittsackH., WenserskiF., KollerH., & ArendtG.Basal ganglia metabolite abnormalities in minor motor disorder associated with human immunodeficiency virus type 1. Archives of Neurology2001; 58(8): 1281–1286.
36.
BrandA., Richter-LandsbergC., & LeibfritzD.Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Developmental Neurosciences1993; 15: 289–298.
37.
WilkinsonI., PaleyM., MiszkielK., Hall-CraggsM., KendallB., ChinnR., & MJH. Cerebral volumes and spectroscopic proton metabolites on MR: is sex important?Magnetic Resonance Imaging1997; 15(2): 243–248.
38.
PouwelsP., & FrahmJ.Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magnetic Resonance in Medicine1998; 39(1): 53–60.
39.
KomoroskiR., HeimbergC., CardwellD., & KarsonC.Effects of gender and region on proton MRS of normal human brain. Magnetic Resonance Imaging1999; 17(3): 427–433.
40.
GendelmanH., ZhengJ., CoulterC., GhorpadeA., CheM., ThylinM., RubockiR., PersidskyY., HahnF., ReinhardJ.J., & SwindellsS.Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. Journal of Infectious Disease1998; 178(4): 1000–1007.
41.
LezakM.D.Neuropsychological Assessment. Third Edition1995. New York: Oxford University Press.
42.
SacktorN., TarwaterP., SkolaskyM., McArthurJ., SelnesO., BeckerJ., CohenB., MillerE., & the Multicenter, A.I.D.S. Cohort Study. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology2001; 57(3): 542–544.
43.
SacktorN., SkolaskyR., TarwaterP., McArthurJ., SelnesO., BeckerJ., CohenB., & MillerE.The relationship between viral load response to highly active antiretroviral therapy and psychomotor speed performance in HIV+ homosexual men. Journal of Neurovirology2002; 8(Suppl. 1): 15.
44.
SchmittF., BigleyJ., McKinnisR., LogueP., EvansR., & DruckerJ.Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine1988; 319(24): 1573–1578.
45.
SegalM.The blood–CSF barrier and the choroid plexus. In Introduction to the Blood–Brain Barrier.1998; pp. 251–258. Edited by PardridgeW.Cambridge, UK: Cambridge University Press.
46.
BergerJ., NathA., GreenbergR., AndersenA., GreeneR., RognarA., & AvisonM.Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology2000; 54(4): 921–926.
